These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31615451)

  • 1. Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.
    Tolksdorf J; Kattan MW; Boorjian SA; Freedland SJ; Saba K; Poyet C; Guerrios L; De Hoedt A; Liss MA; Leach RJ; Hernandez J; Vertosick E; Vickers AJ; Ankerst DP
    BMC Med Res Methodol; 2019 Oct; 19(1):191. PubMed ID: 31615451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
    Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
    Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accommodating heterogeneous missing data patterns for prostate cancer risk prediction.
    Neumair M; Kattan MW; Freedland SJ; Haese A; Guerrios-Rivera L; De Hoedt AM; Liss MA; Leach RJ; Boorjian SA; Cooperberg MR; Poyet C; Saba K; Herkommer K; Meissner VH; Vickers AJ; Ankerst DP
    BMC Med Res Methodol; 2022 Jul; 22(1):200. PubMed ID: 35864460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Jones JS; Cronin AM; Roobol MJ; Hugosson J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ; Thompson IM
    World J Urol; 2014 Feb; 32(1):185-91. PubMed ID: 22527674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
    World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
    Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
    Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer risk assessment tools in an unscreened population.
    Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
    World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
    Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
    Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Pereira-Azevedo N; Braga I; Verbeek JF; Osório L; Cavadas V; Fraga A; Carrasquinho E; Cardoso de Oliveira E; Nieboer D; Roobol MJ
    Int J Urol; 2017 Dec; 24(12):826-832. PubMed ID: 28901582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
    PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.
    Strobl AN; Thompson IM; Vickers AJ; Ankerst DP
    J Urol; 2015 Jul; 194(1):58-64. PubMed ID: 25636656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
    Roobol MJ; Schröder FH; Hugosson J; Jones JS; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Ankerst D; Bartsch G; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Freedland SJ; Moreira DM; Vickers AJ; Lilja H; Steyerberg EW
    World J Urol; 2012 Apr; 30(2):149-55. PubMed ID: 22203238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
    Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
    J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
    Williams SB; Salami S; Regan MM; Ankerst DP; Wei JT; Rubin MA; Thompson IM; Sanda MG
    Cancer; 2012 May; 118(10):2651-8. PubMed ID: 22006057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.